Elicio Therapeutics, Inc. (ELTX) – What Are Researchers Thinking About This Stock?

Shares of Elicio Therapeutics, Inc. (NASDAQ:ELTX) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $15.00.

Several brokerages have recently issued reports on ELTX. Wall Street Zen raised shares of Elicio Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Elicio Therapeutics in a research note on Tuesday, October 27th. B. Riley Financial cut their price target on Elicio Therapeutics to $8.00 and set a “buy” rating on the stock in a report on Thursday, September 24th. Finally, HC Wainwright reissued a “buy” rating on shares of Elicio Therapeutics in a report on Tuesday, August 18th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Shah Capital Management bought a new stake in shares of Elicio Therapeutics during the third quarter valued at about $2,275,000. BlackRock Inc. bought a new position in Elicio Therapeutics in the 2nd quarter valued at about $2,995,000. Renaissance Technologies LLC grew its position in Elicio Therapeutics by 332.7% in the 1st quarter. Renaissance Technologies LLC now owns 121,631 shares of the company’s stock valued at $1,300,000 after buying an additional 93,520 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in Elicio Therapeutics during the 2nd quarter valued at about $62,000. Finally, Bank of America Corp DE increased its stake in Elicio Therapeutics by 1,225.2% during the 1st quarter. Bank of America Corp DE now owns 15,333 shares of the company’s stock valued at $164,000 after buying an additional 14,176 shares during the period. 35.03% of the stock is owned by institutional investors and hedge funds.

Elicio Therapeutics Stock Performance

Shares of NASDAQ:ELTX traded up $0.11 during trading on Friday, reaching $1.51. 756,123 shares of the company’s stock traded hands, compared to its average volume of 285,067. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.77 and a quick ratio of 2.77. Elicio Therapeutics has a 12 month low of $1.25 and a 12 month high of $16.00. The company has a 50 day moving average of $1.91 and a 200-day moving average of $6.58. The stock has a market capitalization of $40.91 million, a P/E ratio of -0.81 and a beta of 1.64.

Elicio Therapeutics (NASDAQ:ELTX) last issued its earnings results on Thursday, November 5th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.14. On average, equities analysts expect that Elicio Therapeutics will post -1.90 EPS for the current year.

Elicio Therapeutics Company Profile

Elicio Therapeutics, Inc (NASDAQ: ELTX) is a clinical-stage biotechnology company developing immunotherapies designed to activate the immune system against cancer. The company’s approach is based on its proprietary Amphiphile technology, which is intended to direct vaccine components and immune-stimulating agents to lymph nodes, where important immune responses are initiated.

Elicio’s lead program is ELI-002, a therapeutic cancer vaccine being developed for patients with tumors containing mutations in the KRAS gene.